| Literature DB >> 30530580 |
Torunn Hatlen Nøst1,2, Aslak Steinsbekk1, Ola Bratås1,2, Kjersti Grønning1,2.
Abstract
OBJECTIVES: To investigate the effects on persons with chronic pain after 3 months of a group-based chronic pain self-management course compared with a drop-in, low-impact outdoor physical group activity on patient activation and a range of secondary outcomes.Entities:
Keywords: clinical trial; pain management; primary care
Mesh:
Year: 2018 PMID: 30530580 PMCID: PMC6303596 DOI: 10.1136/bmjopen-2018-023017
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Outline of the self-management course
| Session: | Main topics |
| 1 | What is pain? Understanding the difference between acute and chronic pain. |
| 2 | My challenges. What stops me in achieving what I want? |
| 3 | How to cope better in everyday life? |
| 4 | Goal setting. |
| 5 | ‘I can- I have a choice!’. |
| 6 | The way ahead. |
Figure 1Participants flow through the study.
Participants’ characteristics at baseline
| Characteristics | INTV (n=60) | CTRL (n=61) |
| Female, n (%) | 53 (88.3 %) | 53 (86.9 %) |
| Age years, mean (SD) | 52.1 (11.4) | 53.3 (12.1) |
| (range) | (27–71) | (23–74) |
| Living with someone, n (%) | 43 (71.7) | 43 (70.5) |
| Highest level of education, n (%) | ||
| Lower secondary school or less | 4 (6.7) | 4 (6.6) |
| Upper secondary school | 28 (46.7) | 28 (45.9) |
| Higher education (college or university) | 28 (46.7) | 29 (47.5) |
| Main reason for pain, n (%) | ||
| Musculoskeletal diseases, ICPC-2 chapter L | 46 (76.7) | 47 (77.0) |
| Neuro system diseases, ICPC-2 chapter N | 10 (16.7) | 6 (9.8) |
| General and unspecified, ICPC-2 chapter A | 4 (6.7) | 8 (13.1) |
| Pain duration, n (%) | ||
| 7–11 months | 2 (3.3) | 0 (0) |
| 1–5 years | 12 (20.0) | 12 (19.7) |
| 6–9 years | 11 (18.3) | 8 (13.1) |
| ≥10 years | 35 (58.3) | 41 (67.2) |
| More than one chronic condition, n (%) | 32 (53.3) | 44 (72.1) |
| Work status, n (%) | ||
| Working, full or part time | 13 (21.7) | 18 (29.5) |
| Disability pension, full or graded | 33 (55) | 23 (37.7) |
| Sick leave, full or graded | 8 (13.3) | 12 (19.7) |
| Retired | 6 (10.0 %) | 8 (13.1 %) |
| Pain medication, n (%) | ||
| Prescription only | 23 (38.3) | 28 (45.9) |
| Without prescription | 19 (31.7) | 22 (36.1) |
| Do not use pain medication | 18 (30.0) | 11 (18.0) |
| Healthcare utilisation, last 3 months | ||
| Visits general practitioner, mean (SD) | 1.6 (1.7) | 2.1 (2.0) |
| Visits physiotherapist, mean (SD) | 4.5 (5.9) | 5.1 (6.8) |
| Stays rehabilitation centre, mean (SD) | 0.1 (0.3) | 0.05 (0.2) |
| Visits hospital outpatient clinic, mean (SD) | 0.5 (0.9) | 0.6 (1.3) |
| Admission hospital, mean (SD) | 0.2 (1.0) | 0.02 (0.1) |
| Number of days, mean (SD) (range) | 0.2 (1.2) (0–8) | 0.02 (0.1) (0–1) |
CTRL, control group; ICPC- 2, International Classification of Primary Care, Second Edition; INTV, intervention group.
Observed mean (SD) at baseline and 3 months, and estimated differences (95% CIs) within groups from baseline to 3 months and difference between groups at 3 months
| Group | Observed | Estimated | |||||
| Within groups Baseline to 3 months | Between groups 3 months | ||||||
| Baseline mean (SD) | 3 months mean (SD) | Difference (95% CI) | P value | Difference (95% CI) | P value | ||
|
| INTV | 63.9 (13.2) | 64.3 (14.3) | 0.4 (−2.9 to 3.6) | 0.829 | −0.5 (−4.8 to 3.7) | 0.802 |
| (0–100)↑ | CTRL | 63.0 (12.9) | 64.2 (12.0) | 0.9 (−2.3 to 4.0) | 0.576 | ||
|
| INTV | 18.2 (6.5) | 17.1 (7.2) | −1.1 (−2.6 to 0.5) | 0.171 | −0.6 (−2.6 to 1.5) | 0.599 |
| (0–10)↓ | CTRL | 18.8 (5.6) | 18.1 (7.7) | −0.5 (−2.1 to 1.0) | 0.520 | ||
|
| INTV | 29.2 (14.0) | 28.4 (13.9) | −1.5 (−5.1 to 2.1) | 0.419 | −0.3 (−5.1 to 4.6) | 0.913 |
| (0–10)↓ | CTRL | 32.6 (13.1) | 30.1 (17.5) | −1.2 (−4.9 to 2.4) | 0.516 | ||
|
| INTV | 3.4 (3.3) | 4.0 (3.2) | 0.6 (−0.1 to 1.2) | 0.115 | 1.0 (0.01 to 1.9) | 0.047 |
| (0–10)↑ | CTRL | 3.5 (2.9) | 3.0 (2.8) | −0.4 (−1.1 to 0.3) | 0.268 | ||
|
| INTV | 62.7 (18.2) | 54.8 (20.2) | −7.9 (−13.1 to −2.7) | 0.003 | −1.4 (−8.0 to 5.3) | 0.691 |
| (0–100)↓ | CTRL | 62.8 (15.1) | 56.1 (20.6) | −6.6 (−11.8 to −1.4) | 0.014 | ||
|
| INTV | 4.4 (3.0) | 4.6 (3.4) | 0.1 (−0.6 to 0.8) | 0.844 | 0.03 (−0.9 to 1.0) | 0.955 |
| (0–21)↓ | CTRL | 5.1 (3.1) | 4.9 (3.7) | 0.04 (−0.7 to 0.7) | 0.902 | ||
|
| INTV | 7.8 (3.4) | 7.5 (4.2) | −0.5 (−1.2 to 0.2) | 0.159 | −0.7 (−1.6 to 0.2) | 0.147 |
| (0–21)↓ | CTRL | 8.1 (3.6) | 8.3 (3.7) | 0.2 (−0.5 to 0.8) | 0.558 | ||
|
| INTV | 38.1 (10.5) | 38.7 (12.0) | 0.7 (−1.9 to 3.2) | 0.594 | 1.7 (−1.7 to 5.1) | 0.332 |
| (0–60)↑ | CTRL | 37.5 (10.4) | 37.0 (11.7) | −1.0 (−3.5 to 1.5) | 0.439 | ||
|
| INTV | 61.4 (12.4) | 62.1 (13.4) | 0.6 (−1.6 to 2.8) | 0.590 | 0.1 (−3.0 to 3.1) | 0.972 |
| (13- 91)↑ | CTRL | 61.8 (13.0) | 62.8 (12.7) | 0.6 (−1.7 to 2.8) | 0.623 | ||
|
| INTV | 0.63 (0.14) | 0.61 (0.16) | −0.01 (−0.04 to 0.02) | 0.641 | −0.04 (−0.1 to 0.01) | 0.095 |
| (0–1)↑ | CTRL | 0.61 (0.14) | 0.64 (0.18) | 0.02 (−0.003 to 0.06) | 0.071 | ||
|
| INTV | 46.3 (21.3) | 44.8 (18.9) | −1.0 (−6.6 to 4.6) | 0.729 | 2.3 (−4.9 to 9.4) | 0.531 |
| (0–100)↑ | CTRL | 43.4 (18.5) | 41.3 (19.5) | −3.3 (−8.8 to 2.3) | 0.251 | ||
|
| INTV | 2.1 (0.89) | 2.4 (0.93) | 0.2 (0.01 to 0.4) | 0.032 | 0.2 (−0.1 to 0.4) | 0.153 |
| (1- 5)↑ | CTRL | 2.2 (0.69) | 2.2 (0.88) | 0.02 (−0.2 to 0.2) | 0.846 | ||
|
| INTV | 4.0 (0.87) | 4.0 (1.06) | 0.1 (−0.1 to 0.3) | 0.527 | 0.1 (−0.2 to 0.4) | 0.557 |
| (1- 5)↑ | CTRL | 4.0 (1.02) | 3.9 (0.73) | −0.01 (−0.2 to 0.2) | 0.875 | ||
|
| INTV | 12.5 (4.1) | 12.6 (5.6) | 0.2 (−0.8 to 1.2) | 0.660 | −0.7 (−2.0 to 0.7) | 0.353 |
| ↑ | CTRL | 11.5 (4.0) | 12.7 (4.7) | 0.9 (−0.1 to 1.9) | 0.086 | ||
Estimates presented are from linear mixed effects model (unadjusted) without random slope.
The numbers of participants for each outcome at 3 months varied between 97 and 104 due to some missing responses
↑Increase in scores indicates improvement.
↓Decrease in scores indicates improvement.
AIOS, Arizona Integrative Outcome Scale; BPI, Brief Pain Inventory; CTRL, control group; EQ-5D-5L, EuroQoL 5 dimensions 5 level; HADS, Hospital Anxiety and Depression Scale; INTV, intervention group; PAM-13, Patient Activation Measure; PSEQ, Pain Self-Efficacy Questionnaire; SOC-13, Sense of Coherence; VAS, visual analogue scale.